The takeaway from Eckert & Ziegler’s Q1 results is positive: Medical delivered strong underlying growth without licence revenues, while Isotope Products offers a recovery lever for the rest of the year. At group level, fx-adj. sales rose 11% yoy to € 72.9m, while reported sales rose 7% yoy. Adj. EBIT came in roughly flat yoy at € 16m, with the margin declining 1.8pp yoy to 21.9%.
LÄS MER
